Evidence map›Paper›PMID 41530253›Full record

ArticleScientific reports2026

Proteomic analysis of endothelial progenitor cells secretome identifies Serpine 1 as a potent regulator of osteogenesis.

Thabet Asbi, Tal Tamari, Ofri Doppelt-Flikshtain, Oshrat Regev-Yehishalom, Itay Zusmanovich, Amin Younis, Tahel Oguen-Alon, Tal Berg, Havazelet Bianco-Peled, Hadar Zigdon-Giladi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Thabet AsbiDepartment of Periodontology, Rambam Health Care Campus, Haifa, Israel.
Tal TamariLaboratory for Bone Repair, CRIR Institute, Rambam Health Care Campus, Haifa, Israel.
Ofri Doppelt-FlikshtainLaboratory for Bone Repair, CRIR Institute, Rambam Health Care Campus, Haifa, Israel.
Oshrat Regev-YehishalomDepartment of Chemical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Itay ZusmanovichDepartment of Chemical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Amin YounisDepartment of Periodontology, Rambam Health Care Campus, Haifa, Israel.
Tahel Oguen-AlonDepartment of Prosthodontics, Rambam Health Care Campus, Haifa, Israel.
Tal BergLaboratory for Bone Repair, CRIR Institute, Rambam Health Care Campus, Haifa, Israel.
Havazelet Bianco-PeledDepartment of Chemical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Hadar Zigdon-GiladiDepartment of Periodontology, Rambam Health Care Campus, Haifa, Israel. h_zigdon@rambam.health.gov.il.

Funding

Israel Innovation Authority 3-16221
6 · The paper itself

Abstract

Endothelial progenitor cells (EPCs) exert potent paracrine effect on bone regeneration, yet the specific protein mediators remain incompletely characterized. Through proteomic profiling of EPC-conditioned medium, we identified eight highly secreted proteins with angiogenic and osteogenic potential and were evaluated in vitro using bone marrow human mesenchymal stromal cells (MSCs) and microvascular endothelial cells (HMECs). Proliferation (XTT assay), migration (scratch assay), and osteogenic differentiation (ALP and Alizarin Red staining) were assessed. Serpine-1 significantly increased MSC and HMEC proliferation in a dose-dependent manner and enhanced osteogenic differentiation. Migration was primarily driven by platelet-derived growth factor subunit B (PDGFB) and BMP2. Based on its dual bioactivity, Serpine-1 was encapsulated in PLGA microspheres embedded in a collagen scaffold (Col-Micro-Serpine) and applied to 4-mm calvarial defects in mice (C57BL/6JOIaHsd, Female, 6 weeks old, 20-25 g). Defects filled with collagen and empty microspheres (Col-Micro) served as control. Micro-CT analysis revealed significantly enhanced bone volume (0.036 ± 0.033, 0.003 ± 0.003 mm3, p < 0.01), BV/TV ratio (2.71 ± 2.91, 0.24 ± 0.27%, p < 0.05), bone density (0.78 ± 0.68, 0.13 ± 0.11 1/mm, p < 0.01 ), and trabecular thickness (0.01 ± 0.05, 0.04 ± 0.04 mm, p < 0.05) in Col-Micro-Serpine versus Col- Micro groups respectively. De novo bone formation within the defect center was observed exclusively in the Col-Micro-Serpine group. This study establishes Serpine-1 as a previously unrecognized osteogenic cue and presents a novel sustained-delivery platform for its application in bone regeneration. These findings offer new insights into cell-free regenerative strategies and highlight Serpine-1 as a promising therapeutic target in skeletal tissue engineering.

Indexed as

Endothelial Progenitor CellsOsteogenesisPlasminogen Activator Inhibitor 1ProteomicsSecretomeAnimalsBone RegenerationCell DifferentiationCell MovementCell ProliferationCells, CulturedFemaleHumansMesenchymal Stem CellsMiceMice, Inbred C57BLPlasminogen Activator Inhibitor 1SERPINE1 protein, humanBone regenerationSerpine-1Tissue engineering

Identifiers

PMID41530253
PMCPMC12881378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.